Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 126, Issue 3-5, 2011, Pages 113-120

  Xie, Ya ^a   Wang, Yan Ling ^b   Yu, Li ^a   Hu, Qian ^a   Ji, Lei ^b   Zhang, Yan ^a   Liao, Qin Ping ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

AMPK; Endometrial cancer; Mammalian target of rapamycin; Medroxyprogesterone acetate; Metformin; Progesterone receptor

Indexed keywords

ADENYLATE KINASE; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; METFORMIN; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN KINASE B; PROTEIN P70; SOMATOMEDIN C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENTIATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; MEDROXYPROGESTERONE ACETATE; METFORMIN; MODELS, BIOLOGICAL; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 79953644936     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.12.006     Document Type: Article

References (32)

1. D.M. Purdie, A.C. Green, D.M. Purdie, and A.C. Green Epidemiology of endometrial cancer. Best practice & research Clin. Obstet. Gynaecol. 15 3 2001 341 354 (Pubitemid 32631468)
2. J.L. Benedet, H. Bender, J.H. 3rd, H.Y. Ngan, and S. Pecorelli FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers Int. J. Gynaecol. Obstet. 70 2 2000 209 262
3. G. Pitson, T. Colgan, and W. Levin Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients Int. J. Radiat. Oncol. Biol. Phys. 53 4 2002 862 867 (Pubitemid 34722630)
4. W.T. Creasman, K.S. McCarty Sr, T.K. Barton, and K.S. McCarty Jr Clinical correlates of estrogen and progesterone-binding proteins in human endometrial adenocarcinoma Obstetrics and Gynecology 55 3 1980 363 370 (Pubitemid 10129713)
5. C.E. Ehrlich, P.C. Young, F.B. Stehman, G.P. Sutton, W.M. Alford, and W.M. Alford Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium Am. J. Obstet. Gynecol. 158 4 1988 796 807
6. J.T. Thigpen, M.F. Brady, and R.D. Alvarez Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group J. Clin. Oncol. 17 6 1999 1736 1744 (Pubitemid 29269242)
7. C.A. Lange, J.K. Richer, T. Shen, and K.B. Horwitz Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways J. Biol. Chem. 273 47 1998 31308 31316 (Pubitemid 28533147)
8. K.B. Horwitz, and P.S. Alexander In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation Endocrinology 113 6 1983 2195 2201 (Pubitemid 14213588)
9. R.L. Arnett-Mansfield, A. deFazio, and G.V. Wain Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium Cancer Res. 61 11 2001 4576 4582 (Pubitemid 32685792)
10. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N. Engl. J. Med. 348 17 2003 1625 1638 (Pubitemid 36459468)
11. R.N. Roy, A.H. Gerulath, and A. Cecutti Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium Mol. Cell. Endocrinol. 153 1-2 1999 19 27 (Pubitemid 29339153)
12. M Navarro, and R. Baserga Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor Endocrinology 142 3 2001 1073 1081 (Pubitemid 32202816)
13. T. Schmelzle, and M.N. Hall TOR, a central controller of cell growth Cell 103 2 2000 253 262
14. X. Cui, P. Zhang, and W. Deng Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Mol. Endocrinol. 17 4 2003 575 588 (Pubitemid 36403572)
15. Z.Q. Shen, H.T. Zhu, and J.F. Lin Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives Obstet. Gynecol. 112 2 (Pt 2) 2008 465 467
16. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
17. K.H. Lu, W. Wu, and B. Dave Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma Clin. Cancer Res. 14 9 2008 2543 2550
18. H.B. Jefferies, S. Fumagalli, P.B. Dennis, C. Reinhard, R.B. Pearson, and G. Thomas Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k EMBO J. 16 12 1997 3693 3704 (Pubitemid 27250062)
19. L.S. Augustin, L. Dal Maso, and S. Franceschi Association between components of the insulin-like growth factor system and endometrial cancer risk Oncology 67 1 2004 54 59 (Pubitemid 39370351)
20. M.M. Mita, A. Mita, and E.K. Rowinsky Mammalian target of rapamycin: a new molecular target for breast cancer Clin. Breast Cancer 4 2 2003 126 137 (Pubitemid 36939419)
21. Z. Feng, H. Zhang, A.J. Levine, and S. Jin The coordinate reulation of the p53 and mTOR pathways in cells Proc. Natl. Acad. Sci. U. S. A. 102 23 2005 8204 8209 (Pubitemid 40800067)
22. L.C. Cantley, and B.G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. U. S. A. 96 8 1999 4240 4245 (Pubitemid 29190320)
23. G.B. Mills, Y. Lu, and E.C. Kohn Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo Proc. Natl. Acad. Sci. U. S. A. 98 18 2001 10031 10033 (Pubitemid 32802967)
24. G.L. Mutter, M.C. Lin, and J.T. Fitzgerald Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J. Natl. Cancer Inst. 92 11 2000 924 930
25. S.M. Hadad, S. Fleming, and A.M. Thompson Targeting AMPK: a new therapeutic opportunity in breast cancer Crit. Rev. Oncol. Hematol. 67 1 2008 1 7
26. K. Inoki, M.N. Corradetti, and K.L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat. Genet. 37 1 2005 19 24 (Pubitemid 40070934)
27. K. Inoki, Y. Li, T. Zhu, and J. Wu TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling Nat. Cell. Biol. 4 9 2002 648 657 K.L. (Pubitemid 34993700)
28. H.M.G. Vander, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 5930 2009 1029 1033
29. H.E. Vander, S.I. Lee, S. Bandhakavi, T.J. Griffin, and D.H. Kim Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat. Cell Biol. 9 3 2007 316 323 (Pubitemid 46344611)
30. A.J. Scheen Clinical pharmacokinetics of metformin Clin. Pharmacokinet. 30 5 1996 359 371 (Pubitemid 26177181)
31. J.L. Isoda, A. Young, and Zirlik Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells Arterioscler. Thromb. Vasc. Biol. 26 3 2006 611 617
32. W.H. Gotlieb, J. Saumet, and M.C. Beauchamp In vitro metformin anti-neoplastic activity in epithelial ovarian cancer Gynecol. Oncol. 110 2 2008 246 250